Get the Stockscreener App
4.71
6.32%
0.28
After Hours:
4.64
-0.07
-1.49%
Aquestive Therapeutics Inc stock is traded at $4.71, with a volume of 3.02M.
It is up +6.32% in the last 24 hours and up +13.91% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$4.43
Open:
$4.49
24h Volume:
3.02M
Relative Volume:
1.97
Market Cap:
$590.87M
Revenue:
$50.27M
Net Income/Loss:
$-68.91M
P/E Ratio:
-7.8109
EPS:
-0.603
Net Cash Flow:
$-44.32M
1W Performance:
+11.88%
1M Performance:
+13.91%
6M Performance:
-18.93%
1Y Performance:
+38.53%
1-Day Range:
$4.445
$4.7399
1-Week Range:
$4.125
$4.7399
52-Week Range:
$2.93
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.71 | 590.87M | 50.27M | -68.91M | -44.32M | -0.603 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect - ACCESS Newswire
Aquestive Therapeutics (NYSE:AQST): What Insider Activity Reveals About Corporate Confidence - Kalkine Media
Have Aquestive Therapeutics Insiders Been Selling Stock? - simplywall.st
Aquestive Therapeutics Inc (AQST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aquestive Therapeutics Inc (AQST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aquestive Therapeutics Inc (AQST) Institutional Confidence - TradingKey
Aquestive Therapeutics Inc (AQST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aquestive Therapeutics Inc (AQST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aquestive Therapeutics Inc (AQST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aquestive Therapeutics Inc (AQST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aquestive Therapeutics CEO sells $104,010 in company stock By Investing.com - Investing.com Canada
Aquestive Therapeutics CEO sells $104,010 in company stock - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-06-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Krop Julie - Moomoo
Aquestive (AQST) awards Abigail Jenkins 50,500 stock options at $3.99 - Stock Titan
Aquestive Therapeutics (AQST) director receives 50,500 stock options grant - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
AQST: FDA progress, global expansion, and all proposals passed with strong shareholder support - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gew - The National Law Review
AQUESTIVE THERAPEUTICS INC (AQST) Stock Chart - ChartMill
Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire
2026-06-04 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics Q1 earnings call highlights - MSN
AQST: Aquestive TherapeuticsInteractive Chart - Zacks Investment Research
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review
2026-06-02 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics Charts Cautious, Liquid Path Forward - TipRanks
Aquestive Therapeutics CEO sells $35,413 in company stock By Investing.com - Investing.com South Africa
Aquestive Therapeutics CEO sells $35,413 in company stock - Investing.com UK
PRN_FinancialWrapper - FinancialContent
Aquestive secures $150 million debt facility with Oaktree By Investing.com - Investing.com Nigeria
Aquestive targets Q3 FDA resubmission for Anaphylm and projects >$150M cash at launch - MSN
A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $6 to $9 - Moomoo
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
All News about Aquestive Therapeutics, Inc.Common Stock - The Chronicle-Journal
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Aquestive Says It’s on Track to Launch Anaphylm Studies for FDA - Allergic Living
Analysts Have Made A Financial Statement On Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) First-Quarter Report - Moomoo
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2026 Earnings Call Transcript - Insider Monkey
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.23%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):